-
January 18, 2013
InterMune Inc. (ITMN) recently priced its concurrent underwritten public offerings of convertible senior notes and ...
-
January 16, 2013
InterMune Inc. (ITMN) recently announced its intention to raise funds through concurrent underwritten public ...
-
November 19, 2012
The market has been doing well after the morning's trading. The Nasdaq has moved up 1.7%; the S&P 500 has climbed ...
-
November 08, 2012
InterMune Inc.'s (ITMN) third-quarter loss per share of 70 cents was narrower than the Zacks Consensus loss Estimate ...
-
November 08, 2012
This morning's trading has marked a bad day for the market so far. The Nasdaq has fallen 0.5%; the S&P 500 is down ...
-
October 18, 2012
The Nasdaq has decreased 0.3%, the S&P 500 has moved little and the Dow has climbed 0.1% so far today. The ...
-
October 03, 2012
Health Canada recently approved InterMune, Inc.'s (ITMN) Esbriet (pirfenidone) for the treatment of mild-to-moderate ...
-
September 13, 2012
InterMune, Inc. (ITMN) recently announced that the Comite Economique des Produits de Sante (CEPS), the pricing ...
-
September 10, 2012
The Nasdaq has slipped 0.6%, the S&P 500 is unchanged and the Dow is trading up 0.1% after the morning's trading. ...
-
September 04, 2012
InterMune, Inc. (ITMN) recently presented data on Esbriet from the RECAP extension study at the 2012 Annual Congress ...
-
July 24, 2012
InterMune Inc. (ITMN) posted second-quarter loss per share of 78 cents, wider than the year-ago loss of 70 cents and ...
-
June 22, 2012
InterMune Inc. (ITMN) recently completed the sale of its rights to Actimmune to Vidara Therapeutics International ...
-
December 19, 2011
Let's take a look at a few stocks that have recently entered oversold territory because these could be candidates ...
-
January 05, 2011
Check out December's best and worst Healthcare Stocks.
-
December 21, 2010
Possible European approval could save the day for this risky biotech.
-
September 10, 2010
Bristol-Myers is paying a lot, but a successful HCV franchise could be worth much more.
-
May 26, 2010
ASCO is a major event for the pharmaceutical and biotech industry, and these stocks could shine in the limelight.
-
May 13, 2010
Adaptive design is an idea whose time has come, and investors in biotechs and pharmaceuticals should stand to benefit.
-
May 10, 2010
Should investors hang on despite a devastating FDA decision?
-
April 28, 2010
Outperformance can emerge from any sector and for many different reasons.
